PIK3CA
Faeth Therapeutics Closes $47M Series A Round to Explore Precision Diet Cancer Therapy Benefits
In clinical trials, the firm will screen patients for their tumors' nutritional vulnerabilities, and dispense a complete diet to be used alongside drugs.
MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner
Premium
The therapy, which could potentially have tissue-agnostic use, is designed to target a public neoantigen from a mutation in the oncogenic driver gene PIK3CA.
NICE Recommends Against Piqray Combo for PIK3CA-Mutated Metastatic Breast Cancer
The committee said it saw no direct evidence in favor of Piqray-fulvestrant when comparing it against standard treatments and found the cost-effectiveness estimates too high.
Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors
The company is studying its PI3Kα inhibitor as a single agent and in combination with fulvestrant in patients with PI3Kα mutations in the first-in-human trial.
Breast Cancer Study Shows Number of Mutated PIK3CA Alleles Affects Tumor Aggressiveness
Studies in breast tumors revealed a "biphasic"Â relationship between mutant PIK3CA allele dosage and stem cell-like features as well as aggressiveness.